DGAP-Adhoc: Borussia Dortmund GmbH & Co. KGaA implements a

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jun 27, 2014 at 5:00 AM

DGAP-Adhoc: Borussia Dortmund GmbH & Co. KGaA implements a capital increase excluding shareholders' subscription rights - Evonik Industries AG acquires 9 percent of Borussia Dortmund and extends main sponsor agreement

Borussia Dortmund GmbH & Co. KGaA / Key word(s): Capital Increase 27.06.2014 10:43 Dissemination of an Ad hoc announcement according to Â§ 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- The Executive Board of Borussia Dortmund GeschÃ¤ftsfÃ¼hrungs-GmbH, which company is acting as the general partner of Borussia Dortmund GmbH & Co. Kommanditgesellschaft auf Aktien (Partnership Limited by Shares - hereinafter: "the Company"), has, on today's date and with the approval of the Supervisory Board which was granted on this same day, decided to increase the Company's capital stock in return for cash contribution, excluding the subscription rights of the limited shareholders. The capital increase is based upon a resolution of the shareholders' meeting which, on 30 November 2010, had authorised the general partner to resolve a capital increase which has now decided to make partial use of the authorisation established by the respective shareholders' resolution. The Company's stock capital, which presently amounts to 61,425,000.00 EUR, consisting of 61,425,000 non-par value bearer shares, will be increased by an amount of 6,120,011.00 EUR by issuing 6,120,011 new non-par value bearer shares for an issue price of 4.37 EUR per new share. This issue price conforms to the unweighted average closing rate for one share noted at the Exchange Electronic Trading ("Xetra-Handel") at the Frankfurt Stock Exchange as of the last five trading days prior to today's date, minus 5 per cent of the stock exchange price so determined. The new shares will be entitled to a share in profits from the beginning of the Company's business year 2014/2015 (commencing 1 July 2014) on, while they are not entitled to a share in profits as regards the Company's business year 2013/2014. The right to subscribe for the share issues and to receive the new shares has been granted to Evonik Industries AG, Essen, Germany ("Evonik"), and Evonik has undertaken to subscribe for such shares. All further steps to give effect to such capital increase are now being taken. Once the capital increase has been performed, entered in the Commercial Register and thus become effective, the Company's stock capital will have been increased to a total of 67,545,011.00 EUR. Evonik will then be the Company's second largest shareholder with a voting interest of app. 9.06 percent of the Company's increased stock capital. The background of Evonik taking such shareholder's position is the prolongation of the main sponsor agreement which had been in effect since March 2006 and was going to expire at the end of the 2015/2016 football season. Evonik and the Company have agreed upon such extension today, so that the main sponsor agreement will now be in effect until the end of the 2024/2025 season. Evonik is seeking to cement and generally promote its sponsor relationship and further develop its brand partnership. Both, Evonik and the Company, thus create a solid basis for further economical and sporting success also on an international level. The Company is intending to use the gross proceeds of the issue of new shares, amounting to 26,744,448.07 EUR, for the consolidation of its equity base and for creating the option to finance growth accelerating investments without the need to take borrowings. After the capital increase has become effective, the Company still will have authorised capital totalling to 24,592,489.00 EUR available for future capital increases. The Executive Board plans to use the remaining authorised capital or a portion thereof - foreseeably within the first quarter of its business year 2014/2015 (i.e. between 1 July 2014 and 30 September 2014) - for the purpose of performing a corporate action allowing its limited shareholders to acquire new shares. In this context, the Executive Board will continue its exploratory discussions with companies that have an interest in a strategic partnership (see the Company's ad-hoc-disclosure of 6 June 2014). Dortmund, 27 June 2014 Borussia Dortmund GmbH & Co. KGaA Borussia Dortmund GeschÃ¤ftsfÃ¼hrungs-GmbH 27.06.2014 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Borussia Dortmund GmbH & Co. KGaA Rheinlanddamm 207 - 209 44137 Dortmund Germany Phone: 0231/ 90 20 - 2746 Fax: 0231/ 90 20 - 852746 E-mail: aktie@bvb.de Internet: www.bvb.de/aktie // www.aktie.bvb.de ISIN: DE0005493092 WKN: 549309 Indices: SDAX Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, DÃ¼sseldorf, Hamburg, MÃ¼nchen, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...